Overview

Update
Total Equity Funding
$81M in 5 Rounds from 8 Investors
Most Recent Funding
$3.9M Grant on July 21, 2016
Headquarters:
San Diego, CA
Description:
ViaCyte is a preclinical therapeutic company focused on a product which can free type-1 and 2 diabetes patients from insulin dependence.
Founders:
Categories:
Therapeutics, Health Care, Biotechnology
Website:
http://www.viacyte.com
Social:

Company Details

Update

ViaCyte formerly Novocell is a preclinical therapeutic company focused on diabetes. Their therapy is based on the differentiation of stem cells into pancreatic beta cell precursors, with subcutaneous implantation in an encapsulation device. Data in their publications demonstrates that these cells can produce therapeutically relevant levels of insulin in response to blood glucose, and sustain diabetic animals. Their goal is a product which can free both Type 1 and Type 2 patients with diabetes from insulin dependence on a long-term basis, while reducing or eliminating hypoglycemic, microvasculature, and weight-related cardiovascular complications.

Funding Rounds (7) - $101.5M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jul, 2016$3.9M / Grant0
Sep, 2014$16.6M / Grant1
Aug, 2014$20M / Series D0
Aug, 2014$5.4M / Series C0
Jul, 2013$10.6M / Series C2
Jul, 2007$25M / Series C4
May, 2006$20M / Venture8

Current Team (3)

Update

Board Members and Advisors (1)

Update

Offices/Locations (1)

Update
  • Office

    3550 General Atomics Court

    San Diego, CA 92121

    USA

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos